Conditions: Advanced Cancer
Keywords: CS-7017 Advanced Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
This is a study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug. Participants who have not progressed while receiving CS-7017 will continue to benefit from longer administration of the agent.

Detailed description:
This is an open-label non-randomized study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug.

Arms:
arm 1: CS-7017 tablets twice daily at strength ranging from 0.5 mg to 0.75 mg

Interventions: intervention 1: CS-7017
Intervention descriptions: intervention 1: CS-7017 administered orally, twice daily continuously for 6 weeks

Protocol document: